Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21335502 | 0.87 | CA12 (0.33) | — | |
| SCHEMBL15510946 | 0.86 | KDM5A (0.31) | CHRNB2CHRNA4 | |
| SCHEMBL23396341 | 0.84 | KDM5A (0.33) | — | |
| SCHEMBL12788323 | 0.83 | HTR1D (0.36) | — | |
| SCHEMBL12380889 | 0.82 | CHRM2 (0.33) | — | |
| SCHEMBL17662500 | 0.81 | CHRNB2 (0.37) | CHRNB2CHRNA4 | |
| SCHEMBL25438247 | 0.80 | MAPK1 (0.32) | — | |
| SCHEMBL23179731 | 0.78 | PIK3CD (0.46) | — | |
| SCHEMBL19465211 | 0.78 | CHRNB2 (0.34) | CHRNB2CHRNA4 | |
| SCHEMBL12788347 | 0.78 | CA12 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018655-A1 | METHOD OF PRODUCING THIN-FILM | ADEKA CORPORATION (JP) | 2024-01-18 | — | — | US | disclosed |
| US-20230158154-A1 | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A CAMPTOTHECIN MOIETY | TUBULIS GMBH (DE) | 2023-05-25 | — | — | US | disclosed |
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | MEDSHINE DISCOVERY INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20220008448-A1 | METHODS OF TREATING FLT3-MUTATED HEMATOLOGIC CANCERS | CTI BIOPHARMA CORP. | 2022-01-13 | — | — | US | disclosed |
| US-11013696-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2021-05-25 | — | — | US | disclosed |
| US-20210078936-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2021-03-18 | — | — | US | disclosed |
| US-20210069199-A1 | METHODS OF TREATING TRANSPLANT REJECTION | SOBI, INC. | 2021-03-11 | — | — | US | disclosed |
| US-10906867-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2021-02-02 | — | — | US | disclosed |
| US-20190321295-A1 | Method of Encapsulating a Nucleic Acid in a Lipid Nanoparticle Host | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10342761-B2 | Method of encapsulating a nucleic acid in a lipid nanoparticle host | NOVARTIS AG (CH) | 2019-07-09 | — | — | US | disclosed |
| US-7563894-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-07-21 | — | — | US | disclosed |
| US-7514447-B2 | Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors | IRM LLC (BM) | 2009-04-07 | — | — | US | disclosed |
| US-20090012094-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2009-01-08 | — | — | US | disclosed |
| US-20080167308-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-07-10 | — | — | US | disclosed |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
| US-20080139597-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | IRM LLC, A DELAWARE LIMITED LIABILITY COMAPNY (BM) | 2008-06-12 | — | — | US | disclosed |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-05-29 | — | — | US | disclosed |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | IRM LLC (BM) | 2007-06-28 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008448-A1 | METHODS OF TREATING FLT3-MUTATED HEMATOLOGIC CANCERS | FLT3, MCL1, CSF3R | CHRNB2 4281/4885CHRNA4 4548/4885 |
| US-20190321295-A1 | Method of Encapsulating a Nucleic Acid in a Lipid Nanoparticle Host | POLN, POLRMT, RNGTT | CHRNB2 4576/4885CHRNA4 4762/4885 |
| US-20210069199-A1 | METHODS OF TREATING TRANSPLANT REJECTION | JAK1, JAK2, JAK3 | CHRNB2 4788/4885CHRNA4 4823/4885 |
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | PSMA6, PSMC1, PSMA1 | CHRNB2 3711/4885CHRNA4 4569/4885 |
| US-20090012094-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | CHRNB2 254/4885CHRNA4 332/4885 |
| US-20210078936-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | LPAR1, LPAR4, LIPA | CHRNB2 4007/4885CHRNA4 3227/4885 |
| US-10342761-B2 | Method of encapsulating a nucleic acid in a lipid nanoparticle host | POLN, POLRMT, RNGTT | CHRNB2 4576/4885CHRNA4 4762/4885 |
| US-20080139597-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | CHRNB2 254/4885CHRNA4 332/4885 |
| US-10906867-B2 | Lipids and lipid compositions for the delivery of active agents | LPAR1, LPAR4, LIPA | CHRNB2 4007/4885CHRNA4 3227/4885 |
| US-11013696-B2 | Lipids and lipid compositions for the delivery of active agents | PHOSPHO1, SGMS1, LIPA | CHRNB2 4291/4885CHRNA4 4318/4885 |
| US-20230158154-A1 | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A CAMPTOTHECIN MOIETY | CALCR, PTH1R, BCR | CHRNB2 2780/4885CHRNA4 3093/4885 |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | PIGO, GPR52, GPR88 | CHRNB2 915/4885CHRNA4 867/4885 |
| US-20070149538-A1 | Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors | KIT, PRKCH, PRKCE | CHRNB2 254/4885CHRNA4 332/4885 |
| US-20240018655-A1 | METHOD OF PRODUCING THIN-FILM | RTF1, GIGYF2, HAO2 | CHRNB2 2598/4885CHRNA4 2822/4885 |
| US-20080167308-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | CHRNB2 254/4885CHRNA4 332/4885 |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | CHRNB2 899/4885CHRNA4 885/4885 |
| US-20080139559-A1 | DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS | KIT, PRKCH, PRKCE | CHRNB2 254/4885CHRNA4 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.